• Manu Chaudhary Venus Medicine Research Centre, Hill Top Industrial Estate, Bhatoli Kalan, Baddi, H. P.-173205 India
  • Anurag Payasi Venus Medicine Research Centre, Hill Top Industrial Estate, Bhatoli Kalan, Baddi, H. P.-173205 India


Clinical isolates, Gram-negative, Susceptibility, Supime


Objective: Present investigation was undertaken to know the prevalence of extended spectrum beta-lactamases (ESBLs) among the collected isolates and to analyse the antibiotic susceptibility patterns of cefepime/sulbactam, cefepime/tazobactam, imipenem/cilastatin and cefepime against these isolates.

Methods: A total of 1259 clinical samples were collected from patients suspected of bacterial infection between July 2013 to July 2014. These samples were subjected for bacterial identification. The prevalence of ESBLs among these isolates and antibiotic susceptibility testing were carried out according to the recommendations of Clinical Laboratory Standards Institute (CLSI) guidelines (2013).

Results: Out of the samples analyzed, 64.3% (810/1259) samples showed the growth of organisms in the culture medium. Of the 810 organisms, 72.7% (589/810) were ESBL positive. Majority of ESBL producing organisms were obtained from urine (32.2 %) followed by blood (28.5 %), swab (12.7%) and sputum (11.3 %). Pus, Bile and fluid samples samples contributed to 8.1 %, 4.0 %, and 3.0% respectively. The organisms that identified were E. coli (n=255), P. aeruginosa (208), Klebsiella spp. (81), A. baumannii (32), and H. Influenzae (13). Among all drugs tested, cefepime plus sulbactam (Supime) revealed the highest activity against ESBL producing Gram negative organisms. The susceptibility of cefepime plus sulbactam against E. coli, P. aeruginosa, K. pneumoniae, A. baumannii, and H. influenzae was 89.9%, 84.6%, 85%, 90.4% and 100%, respectively which was high compared to cefepime, cefepime plus tazobactam and imipenem plus cilastatin.

Conclusion: Overall, the results of the present study strongly advocate the superiority of cefepime/sulbactam over cefepime/tazobactam, imipenem/cilastatin and cefepime and can be of very effective alternative to treat against the deadly multidrug resistant Gram negative bacteria.



Download data is not yet available.


Barradell LB, Bryson HM. Cefepime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1994;47:471–505.

Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998;3:324–30.

Cordonnier C, Herbrecht R, Pico JL, Gardembas M, Delmer A, Delain M, et al. cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. Clin Infect Dis 1997;24:41–51.

Swartz MN. Use of antimicrobial agents and drug resistance. New Eng J Med 1997;337:491–2.

Widmer AF. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46:656–8.

Rossi S. editor. Australian Medicines Handbook. Adelaide: Australian: Medicines Handbook; 2006.

Jazani NH, Babazadeh H, Sabah Z, Zartoshti M. The evaluation of antibiotic resistance to cefepime in hospital isolates of Pseudomonas aeruginosa. J Med Biomed Sci 2010;9:17.

Satti L, Abbasi S, Qumar TA, Khan MS, Hashmi ZA. In vitro efficacy of cefepime against multi-drug resistant Pseudomonas aeruginosa–an alarming situation in our setup. Open Drug Res J 2011;1:12-6.

Ghafur A, Tayade A, Kannaian P. Clinical profile of patients treated with cefepime/tazobactam: a new ß-lactam/ß-lactamase inhibitor combination. J Microbiol Infect Dis 2012;2:79-86.

Sharma A, Gupta A, Arora A. Cefepime/tazobactam: A new BL/BLI combination against ESBL producing Gram negative Bacilli. Int J Pharm Biomed Sci 2012;3:35-8.

Chaudhary M, Payasi A. Prevalence, genotyping of Escherichia coli and Pseudomonas aeruginosa clinical isolates for oxacillinase resistance and mapping susceptibility behaviour. J Microb Biochem Technol 2014;6:63-7.

Millan B, Ghiglione B, Diaz T, Gutkind G, Araque M. CTX-M-14 beta-lactamase-producing Citrobacter freundii isolated in Venezuela. Ann Clin Microbiol Antimicrob 2011;10:22.

Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003;36:S11-S23.

Dalela G. Prevalence of extended spectrum β-lactamase (ESBL) producers among Gram negative Bacilli from various clinical isolates in a tertiary care hospital at Jhalawar, Rajasthan, India. J Clin Diagn Res 2012;6:182-7.

Hawkey PM. Prevalence and clonality of extended-spectrum β-lactamases in Asia. Clin Microbiol Infect 2008;14:159-65.

Ghafourian S, Sewaki Z, Sadeqhifard N, Mohebi R, Neela VK, Maleki A, et al. The prevalence of ESBLs producing Klebsiella pneumoniae isolates in some major hospitals, Iran. Open Microbiol J 2011;5:91–9.

Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D. Prevalence and antimicrobial susceptibility pattern of extended-spectrum β-lactamase-producing enterobacteriaceae in the united arab emirates. Medical Principles Practice 2008;17:32-6.

Chaudhary M, Payasi A. Molecular characterization and in vitro susceptibilities of β-lactamase producing Escherichia coli, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa and Staphylococcus aureus to CSE1034 and other β-lactams. Asian Pac J Trop Med 2014;7(Suppl 1):S217-S223.

Cheesbrough M. Biochemical tests to identify bacteria. In: District laboratory practice in tropical countries. 2nd ed. Cambridge University Press, UK; 2000. p. 178-87.

Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S23. Wayne, PA; 2013.

Bennet JR, Brodie JL, Benner EJ, Kirby WMM. Simplified, accurate method for antibiotic assay of clinical specimens. Appl Microbiol 1966;14:170-7.

Rajan S, Prabavathy J. Antibiotic sensitivity and phenotypic detection of ESBL producing E. coli strains causing urinary tract infection in a community hospital, Chennai, Tamil Nadu, India. Webmed Central Pharmaceutical Sciences 2012;3(11):WMC003840.

Shafiyabi S, Krishna S, Jeer M, Divya P. Trends in antibiotic resistance pattern among Escherichia coli isolates from patients with urinary tract infection in tertiary care hospital, bellary. Int J Pharm Sci Rev Res 2014;24:43-9.

Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK. High rate of fatal cases of pediatric septicemia caused by Gram-negative bacteria with extended-spectrum beta-lactamases in Dares Salaam, Tanzania. J Clin Microbiol 2005;43:745-9.

Rit K, Nag F, Raj HJ, Maity PK. Prevalence and susceptibility profiles of non-fermentative Gram-negative Bacilli infection in a tertiary care hospital of Eastern India. Indian J Clin Pract 2013;24:451-5.

Benachinmardi KK, Padmavathy M, Malini J, Naveneeth BV. Prevalence of non-fermenting Gram-negative bacilli and their in vitro susceptibility pattern at a tertiary care teaching hospital. J Sci Soc 2014;41:162-6.

Mohanasundaram KM. The antimicrobial resistance pattern in the clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital: 2008-2010 (a 3 year study). J Clin Diagn Res 2011;5:491-4.

Mehta M, Punia JN, Joshu RM. Antibiotic resistance in Pseudomonas aeruginosa strains isolated from various clinical specimens-a retrospective study. Indian J Med Microbiol 2001;19:232.

Kumar AR, Kalpana S. Prevalence and antimicrobial susceptibility pattern of Klebsiella pneumoniae causing urinary tract infection and issues related to the rational selection of antimicrobials. Sch J App Med Sci 2013;1:395-9.

Deris ZZ, Azian Harun A, Shafei MN, Rahman RA, Zohari MR. The prevalence and risk factors of nosocomial Acinetobacter blood-stream infections in tertiary teaching hospital in North Eastern Malaysia. Trop Biomed 2009;26:123-9.

Gaur A, Garg A, Prakash P, Anupurba S, Mohapatra TM. Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care Hospital in North India. J Health Population Nutr 2008;26:183-8.

Garau J, Wilson WW, Wood M, Carlet J. Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility. Clin Microbiol Infect 1997;3:87-101.

Wahid AA, Niranjan GP, Prasad GS. In vitro activity of ceftazidime/sulbactam and cefepime/sulbactam in combination against ESBL producing isolates. UJPB 2014;02:25-8.

Livermore DM, Hope R, Mushtaq S, Warner M. Orthodox and unorthodox clavulanate combinations against extended-spectrum β-lactamase producers. Clin Microbiol Infect 2008;14:189-93.

Khalili H, Dashti-Khavidaki S, Shahidi MR, Abdollahi A, Jafari S, Jahangard-Rafsanjani Z, et al. Changes in Gram negative microorganisms resistance pattern during 4 years period in a referral teaching hospital; a surveillance study. J Pharm Sci 2012;20:28.

Sharif A, Sharif MR, Alizargar J. Antibiotic susceptibility of Gram-negative bacteria to cefazolin and cefepime in Shahidbeheshti Hospital in Kashan. Middle-East J Sci Res 2014;21:368-71.

Jazani NH, Babazadeh H, Sabah Z, Zartoshti M. The evaluation of antibiotic resistance to cefepime in hospital isolates of Pseudomonas aeruginosa. J Med Biomed Sci 2010;9:17.

de Macedo JL, Santos JB. Bacterial and fungal colonization of burn wounds. Mem Inst Oswaldo Cruz 2005;100:535-9.

Endimiani F, Perez F, Bonomo RA. Cefepime: a reappraisal in an era of increasing antimicrobial resistance. Expert Rev Anti Infect Ther 2008;6:805-24.

Zanetti G, Bally F, Greub G, Garbino J, Kinge T, Lew D, et al. Cefepime study group, cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7.



How to Cite

Chaudhary, M., and A. Payasi. “COMPARATIVE IN VITRO ACTIVITY OF SUPIME AGAINST GRAM NEGATIVE CLINICAL ISOLATES”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 7, July 2015, pp. 198-02,



Original Article(s)